Clinical trials: Chemoradiotherapy
Esophageal Squamous Cell Carcinoma
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention…
- Trial name
- NEEDS (NCT04460352)
- Testing
- Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Esophagectomy
- Where
- 12 sites in Canada, Ireland and 3 more
- Volunteers
- 1,020 people
- Sponsor
- Karolinska University Hospital
Rectal Cancer Stage II, Rectal Cancer Stage III
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group.
- Trial name
- NCT04970498
- Testing
- MRI, blood routine test
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University Third Hospital
Rectal Cancer
Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy
Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to…
- Trial name
- GRECCAR12 (NCT02514278)
- Testing
- Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders
- Where
- 29 sites in France
- Volunteers
- 218 people
- Sponsor
- University Hospital, Bordeaux
Lymph Node Metastasis, Neurovascular Invasion
Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）
The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can…
- Conditions
- Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection
- Trial name
- AICRC (NCT06997913)
- Testing
- Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hengchao Yu
Esophageal Carcinoma
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
- Trial name
- NCT06549413
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
- Trial name
- NCT04664504
- Testing
- Concurrent Chemoradiotherapy Radiotherapy, Short-course Radiotherapy, Local dose increase of Short-course Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jing Jin, M.D.
Breast Cancer
Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer
The purpose of this study is to determine whether Cisplatin when given with radiation therapy prior to surgery is effective in improving response to treatment in breast cancer patients.
- Trial name
- NCT00603408
- Testing
- Cisplatin, Radiation Therapy, Mastectomy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Non-small Cell Lung Cancer
A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy
Concurrent chemoradiotherapy (CHRT) is the standard of care for unresectable locally advanced stage III non-small cell lung cancer. However, the optimal combination remains unclear.
- Trial name
- TAXCIS (NCT03371550)
- Testing
- Docetaxel, concomitant radiotherapy, Cisplatin
- Volunteers
- 44 people
- Sponsor
- Centre Antoine Lacassagne
Esophageal Cancer
Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
This trial is going to evaluate the efficacy and safety of IMRT / nab-TP chemotherapy for unresectable esophageal cancer, and to investigate the optimal concurrent chemotherapy regimen for local advanced and unresectable…
- Trial name
- NCT02762474
- Testing
- nab-paclitaxel group
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00014118
- Testing
- carboplatin, paclitaxel, conventional surgery
- Where
- 47 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Cervix Cancer
COL Immunotherapy Before Radiochimio + Ipilimumab
This is a multicenter, single arm pilot study evaluating the biological impact of "Nivolumab + Ipilimumab" in patients with cervical squamous cell carcinoma requiring RT-CT as initial therapy
- Trial name
- COLIBRI (NCT04256213)
- Testing
- Nivolumab and Ipilimumab
- Where
- 8 sites in France
- Volunteers
- 40 people
- Sponsor
- ARCAGY/ GINECO GROUP
Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004089
- Testing
- filgrastim, fluorouracil, hydroxyurea
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Esophageal Cancer
Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00628368
- Testing
- Gene expression analysis
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Neoplasms
Fish Oil Supplement in Rectal Cancer
Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases.
- Trial name
- NCT02534389
- Testing
- omega-3 fish oil
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Locally Advanced Rectal Cancer
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
The Efficacy and Safety of Long-Course Preoperative Chemoradiotherapy Combined with Consolidation or Induction NALIRIFOX Chemotherapy in the Treatment of Locally Advanced Rectal Cancer: A Prospective, Multicenter, Phase II Study.
- Trial name
- NCT06894797
- Testing
- Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer
Preoperative chemoradiation therapy is the preferred initial treatment option for distal rectal cancers. However, assessing tumor response to preoperative chemoradiation therapy remains a challenge to the colorectal surgeon…
- Trial name
- NCT00254683
- Testing
- PET/CT with FDG
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo
Cervical Cancers
Toripalimab for High-risk Locally Advanced Cervical Cancer
This phase II clinical study assesses the efficacy and safety of Toripalimab combined with chemoradiotherapy (CRT) followed by Toripalimab maintenance in treating high-risk locally advanced cervical cancer (HR-LACC).
- Trial name
- NCT06416696
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cervical Cancer
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer
Perspectives: To analyse if the change of specific immune response will correlate with clinical effect of advanced cervix cancer after radio-chemotherapy.
- Trial name
- NCT03559803
- Testing
- Cisplatin
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Sichuan University
Nasopharyngeal Carcinoma
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in each group.
- Trial name
- NCT02907710
- Testing
- Endostar, DDP
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Pancreatic Cancer
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
To seek preliminary evidence of antitumor activity (progression free survival) of Erlotinib in combination with standard adjuvant chemoradiation and chemotherapy in patients with resected adenocarcinoma of the pancreas.
- Trial name
- NCT00313560
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.